A detailed history of Pnc Financial Services Group, Inc. transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, Pnc Financial Services Group, Inc. holds 1,952 shares of BBIO stock, worth $46,301. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,952
Previous 838 132.94%
Holding current value
$46,301
Previous $21,000 133.33%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$23.91 - $31.3 $26,635 - $34,868
1,114 Added 132.94%
1,952 $49,000
Q2 2024

Aug 09, 2024

BUY
$23.0 - $31.04 $6,118 - $8,256
266 Added 46.5%
838 $21,000
Q1 2024

May 10, 2024

SELL
$27.35 - $40.45 $683 - $1,011
-25 Reduced 4.19%
572 $17,000
Q4 2023

Feb 09, 2024

SELL
$24.02 - $43.89 $1,104 - $2,018
-46 Reduced 7.15%
597 $24,000
Q1 2023

May 15, 2023

SELL
$7.17 - $18.55 $831 - $2,151
-116 Reduced 15.28%
643 $10,000
Q4 2022

Feb 10, 2023

BUY
$6.74 - $11.52 $208 - $357
31 Added 4.26%
759 $5,000
Q2 2022

Aug 12, 2022

BUY
$5.21 - $12.14 $2,625 - $6,118
504 Added 225.0%
728 $6,000
Q1 2022

May 12, 2022

BUY
$7.34 - $17.16 $1,042 - $2,436
142 Added 173.17%
224 $2,000
Q4 2021

Feb 11, 2022

SELL
$11.38 - $53.41 $59,813 - $280,722
-5,256 Reduced 98.46%
82 $1,000
Q3 2021

Nov 05, 2021

BUY
$46.87 - $64.24 $6,749 - $9,250
144 Added 2.77%
5,338 $250,000
Q2 2021

Aug 06, 2021

SELL
$46.47 - $63.93 $38,755 - $53,317
-834 Reduced 13.84%
5,194 $316,000
Q1 2021

May 07, 2021

BUY
$55.47 - $72.35 $101,621 - $132,545
1,832 Added 43.66%
6,028 $371,000
Q4 2020

Feb 12, 2021

BUY
$38.38 - $71.11 $159,660 - $295,817
4,160 Added 11555.56%
4,196 $298,000
Q3 2020

Nov 06, 2020

SELL
$27.2 - $42.19 $136 - $210
-5 Reduced 12.2%
36 $1,000
Q2 2020

Aug 07, 2020

BUY
$22.22 - $35.69 $911 - $1,463
41 New
41 $1,000

Others Institutions Holding BBIO

About BridgeBio Pharma, Inc.


  • Ticker BBIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 148,246,000
  • Market Cap $3.52B
  • Description
  • BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...
More about BBIO
Track This Portfolio

Track Pnc Financial Services Group, Inc. Portfolio

Follow Pnc Financial Services Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pnc Financial Services Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pnc Financial Services Group, Inc. with notifications on news.